The genetic polymorphism affecting the CYP3A5 enzyme is responsible for inter-individual and interethnic variability in the metabolism of CYP3A5 substrates. The aim of this study was to analyze the distribution of the most common CYP3A5*3 allelic variants in the healthy population of R. Macedonia and to investigate if the allelic frequency falls within the assumed range for European Caucasians. The total of 174 healthy volunteers from the general population were included. The genotyping of the CYP3A5*3 variant alleles, *3A (rs15524) and *3E (rs28365095), was performed with Real-Time PCR based on the allelic discrimination method using a TaqMan SNP genotyping assay according to the manufacturer's instructions. The CYP3A5*3 allele is abundantly present displaying an allelic frequency of 0.922. We estimate that 0.82 of the Macedonian population are homozygotes for the variant and do not have a CYP3A5 enzymatic activity.
Introduction
Isoforms of the cytochrome P450 (CYP) 3A subfamily are the most abundantly expressed CYP enzymes in the human liver. They participate in the metabolism of endogenous compounds, bile acids and steroids (such as aldosterone, testosterone, and estrogens), but also in the biotransformation of approximately 50% of the currently marketed drugs (steroids, antidepressants, immunosuppressive agents and antibiotics) (Paine et al., 2006) .
Substantial inter-individual differences in the CYP3A enzyme expression contribute to the divergence in oral bioavailability and systemic clearance of CYP3A substrates.
Estimates of the relative involvement of a genetic variation relevant to the CYP3A function indicate that 70 to 90% of inter-individual variability is attributable to genetic factors (He et al., 2006) .
The CYP3A gene family consists of four genes (CY-P3A4, CYP3A5, CYP3A7, and CYP3A43) clustered in a region of about 220 kb in chromosome 7q21 (Kuehl et al., 2001; Garsa et al., 2005) . In human adults, CYP3A4 and CYP3A5 are the predominant functional CYP3A isoforms. Although single nucleotide polymorphisms (SNPs) have been found in the coding region of CYP3A4, they are rare and appear to have limited impact on CYP3A4 and the total CYP3A activity. CYP3A5 is the primary extrahepatic CYP3A isoform and typically displays a decreased catalytic activity compared to CYP3A4. So far, 13 genetic polymorphisms have been described for CYP3A5 (Huang et al., 2004) . The genetic basis for polymorphically expressed CYP3A5 has been associated with SNP in intron 3 of the CYP3A5 gene (CYP3A5*3C; g.6986A>G) (King et al., 2003) . CYP3A5*3C mutant allele is the major defective allele, leading to alternative splicing and protein truncation, which in turn results in the absence of the enzyme activity. This variant is the only one reported in all ethnic groups and is therefore considered the most ancient allele. SNPs in the 3′UTR (CYP3A5*3A, g. 31611C>T) and in the intron 10 (CYP3A5*3U, g. 27050A>G) of the CY-P3A5 gene occur in a tight linkage disequilibrium with the CYP3A5*3C variant. All of these linkages cause functionally defective alleles (Bussi and Createil., 2005; Lakhman et al., 2009) . Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, it may be the most important genetic contributor to inter-individual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines (Kuehl et al., 2001) . The relevance of CYP3A5 genotyping will depend on the contribution of this enzyme to the total CYP3A-mediated metabolism of a specific drug. For many drugs, this contribution is not exactly known (Huang et al., 2004) .
The frequency of the most common CYP3A5*3 variant alleles differs among populations and races, ranging from 27-50% in the African-American population, 60-70% among Asians, and up to 85-95% in individuals of Caucasian ancestry, in which the expresser variant (CYP3A5*1) is uncommon (Park et al., 2008; Coto et al., 2010; Gebeyehu et al., 2011) . In addition to the diverse CYP3A5*3 frequency across human populations, there are remarkable ethnic-related differences with regard to the frequency of CYP3A5 variants, with an excess of rare variants (Thompson et al., 2004; Sinues et al., 2007; Azarpira et al., 2011) . There has been no detailed allele and diplotype analysis of the most common CYP3A5 genetic variant in the Macedonian population.
The objective of this study was therefore to analyze the distribution of the most common CYP3A5 allelic variants in the healthy population of R. Macedonia and to investigate if the allelic frequency falls within the assumed range for European Caucasians.
Materials and methods

Study population and DNA isolation
After receiving informed consent, we obtained EDTA whole blood from 194 unrelated healthy donors of a Caucasian origin who self-reported as ethnic Macedonians. Genomic DNA was isolated using Proteinase K digestion, phenol chloroform extraction and ethanol precipita- Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia tion. DNA yields and purity were estimated by measuring the absorbance at 260 nm and 260/280 nm, respectively [NanoDrop 2000, Thermo Scientific] and DNA integrity was confirmed with electrophoresis in 0,8% agarose gels, stained with ethidium bromide. The Ethical Committee of the Ministry of Health of R. Macedonia approved the study. All personal identifiers were removed and the isolated DNA samples were tested anonymously.
Genotyping procedures
The designations of all CYP450 alleles refer to those defined by the Cytochrome P450 Allele Nomenclature Committee (http://www.cypalleles.ki.se/). The genotyping of the CYP3A5*3 variant alleles, *3A (rs15524) and *3E (rs28365095), was performed with Real-Time PCR based on the allelic discrimination method [MxPro 3005P, Stratagene, La Jolla, CA, USA] using a TaqMan SNP genotyping assay according to the manufacturer's instructions [Applied Biosystems, Foster City, CA, USA].
Statistical Analysis
All statistical analyses were performed using the SISA statistical platform. Observed genotype distributions were assessed for the Hardy-Weinberg equilibrium with a X 2 test. Frequency analyses of an inter-population diversity of the examined polymorphisms were performed on data reported for apparently healthy control populations from several different geographic regions in Europe. The difference in CYP3A5 allelic frequencies between our and other ethnic populations was evaluated using the Chi-squared analysis and 
Results
Genotyping for the CYP3A5*3 allele, CYP3A5*3A (g.31611 C>T) and CYP3A5*3E (g. 27050 A>G), was successively performed in the total of 174 subjects. The genotype distribution of the CYP3A5*3 variants is summarized in Table 1 . Table 2 shows the results of the diplotype analyses. The frequency distributions were consistent with the Hardy-Weinberg equilibrium (P >0.05), indicating that the volunteer pool in this study was likely a representative sample of the population being studied. The CYP3A5*3A allele was found in 172 subjects with an allelic frequency of 0.908, while CYP3A5*3E was found in 42 subjects with an allelic frequency of 0.129. Overall, the frequency of the CYP3A5*3 diplotype was estimated at 0.922 (Table 3 ). The CYP3A5*3 variant allele frequency in the healthy population of R. Macedonia com- Table 4 .
Discussion
Various ethnic groups show different frequencies of CYP450 allelic variants, probably due to ancient migrations of geographically distinct and isolated human groups, combined with the influences of selective factors, such as diet or disease (Lee et al., 2003) .
Inter-individual variability in the clearance of CY-P3A substrates can result from the effects of inducers, inhibitors, or genetic or dietary factors that potentially lead to differences in drug toxicity and response. According to the published data, CYP3A5 activity varies within any given ethnic population, suggesting that the genetic variation within the CYP3A5 gene may be the most important contributor to inter-individual and interracial differences in CYP3A-dependent drug clearance and response (Makeeva et al., 2008) . CYP3A5*1 is the only CYP3A5 allele to date that produces high levels of full-length CY-P3A5 mRNA and expresses CYP3A5 while the more common CYP3A5 polymorphism in Caucasians, CYP3A5*3, produces an aberrantly spliced mRNA with a premature stop codon. Marked interethnic differences have been reported for the CYP3A5*3 allelic variant (Roy et al., 2005; Quaranta et al., 2006b ).
The present study documents the distribution of CYP3A5*3 in a population of R. Macedonia. The CYP3A5*3 allele was abundantly present in the subjects of our study, with an allelic frequency of 0.922. We observed no statistically significant difference (p>0.05) compared to CYP3A5*3 frequency data reported for other European ethnic groups. The frequency of the CYP3A5*3 variant allele in our population was interpolated between 0.94 in Greece, Poland, Belgium, Russia and Germany; 0.93 in Bosnian and Herzegovina, Italy and Sweden; 0.92 in Finland, 0.91 in Netherlands, Spain and Croatia; 0.89 in Great Britain and 0.81 in France. This is in good concordance with the described trend of the increasing gradient of CYP3A5*1 allele frequency from north to south of the globe (Suarez-Kurtz et al., 2007) .
The CYP3A5*3 homozygotes lack CYP3A5 expression (non expressors) and are associated with a phenotype of decreased metabolic capacity. Conversely, in individuals with at least one CYP3A5*1 wild type allele, CYP3A5 accounts for at least 50% of the total CYP3A content, and results in a 2-to 3-fold higher total CYP3A catalityc activity (Zeigler-Johnson et al., 2004; Press et al., 2009 ) . This expression variability might be an explanation for the differences in dose requirements in patients who are treated with drugs that are cleared by CYP3A5; CYP3A5*3 homozygotes would require a lower dose of the drug to reach the blood concentration target, compared to CYP3A5*1 homozygotes (Solas et al., 2007; Roco et al., 2012) . However, although several studies have attempted to correlate the metabolic capabilities of different patients with the genotype, a clear relationship between the levels of CYP3A5 expression and/or activity and genetic markers remains to be established (Wang et al., 2012) .
In the studied population of 174 subjects, 0.011 (n = 2) were homozygous for the *1 allele, 0.856 (n = 149) for the *3 allele, and 0.132 (n = 23) were *1/*3 heterozygotes. Since heterozygotes for CYP3A5*3 may have some CY-P3A5 activity, we estimate that 0.86 of the Macedonian population do not have a CYP3A5 enzymatic activity. This is in agreement with the finding that 10% of the Caucasians were high expressers of CYP3A5 (Van Schaik et al., 2002) .
Several lines of evidence suggest that the distribution of CYP3A5 genetic variants in people living in the developing countries may differ from that of people living in industrialized countries due to the selection pressure exerted on specific alleles by different environmental factors present in these geographic areas. To date, most studies on the Cyp3A5 polymorphism have been conducted in populations from industrialized countries (Roy et al., 2005) .
Since no data were available for the Macedonian ethnic group, we would like to emphasize the value of these results, which may serve as a background for comparison with other population samples and could be included in case-control studies as a reference.
Conclusion
Our study demonstrated the high prevalence of CYP3A5*3 allele in the Macedonian population. The distribution of CYP3A5 alleles was similar to that found in other European Caucasians. As the goals of personalized medicine are beginning to be realized, this provides basic information on the CYP3A5 allele frequency for the future pharmacogenetic research in R. Macedonia.
